News Releases

- Top-Line Data from Phase 2 EMPhASIS Trial in Relapsing-Remitting Multiple Sclerosis Expected in Third Quarter 2020 -

Phase 1 Clinical Studies to begin in First Half of 2020

IMU-856 has the potential to address one of the putative root causes of inflammatory bowel disease without impairing the immune system

- Milestone Achieved Nine Months Ahead of Initial Schedule; Top-Line Data Expected in Q3 2020 -

Preclinical Findings Confirm Favorable Profile of IMU-838 as Compared to Teriflunomide in the Potential Treatment of Relapsing-Remitting Multiple Sclerosis

- Unblinded Data Review Committee Recommended Continuation of the Lowest, 10 mg Dose as well as the Highest, 45 mg Dose -

- Study Being Conducted in Collaboration with Investigators at Arizona State University and the Mayo Clinic -

- Phase 2 Trial in Relapsing-Remitting Multiple Sclerosis Expected to be the First Efficacy Read-Out of IMU‑838; Top-line Data Anticipated in Q3 2020 -

- Results confirm IMU-935 as a potent inverse agonist of RORϒt with an IC₅₀ of 24 nM, leading to potent inhibition of Th17 differentiation while allowing normal thymocyte maturation -